Small molecule-mediated refolding and activation of myosin motor function

The small molecule EMD 57033 has been shown to stimulate the actomyosin ATPase activity and contractility of myofilaments. Here, we show that EMD 57033 binds to an allosteric pocket in the myosin motor domain. EMD 57033-binding protects myosin against heat stress and thermal denaturation. In the presence of EMD 57033, ATP hydrolysis, coupling between actin and nucleotide binding sites, and actin affinity in the presence of ATP are increased more than 10-fold. Addition of EMD 57033 to heat-inactivated β-cardiac myosin is followed by refolding and reactivation of ATPase and motile activities. In heat-stressed cardiomyocytes expression of the stress-marker atrial natriuretic peptide is suppressed by EMD 57033. Thus, EMD 57033 displays a much wider spectrum of activities than those previously associated with small, drug-like compounds. Allosteric effectors that mediate refolding and enhance enzymatic function have the potential to improve the treatment of heart failure, myopathies, and protein misfolding diseases. DOI: http://dx.doi.org/10.7554/eLife.01603.001

[1]  Saroj Kumar,et al.  Ultrafast molecular motor driven nanoseparation and biosensing. , 2013, Biosensors & bioelectronics.

[2]  A. Månsson,et al.  Transportation of Nanoscale Cargoes by Myosin Propelled Actin Filaments , 2013, PloS one.

[3]  Cam Patterson,et al.  Proteotoxicity and cardiac dysfunction--Alzheimer's disease of the heart? , 2013, The New England journal of medicine.

[4]  T. Michiue,et al.  Molecular pathology of natriuretic peptides in the myocardium with special regard to fatal intoxication, hypothermia, and hyperthermia , 2012, International Journal of Legal Medicine.

[5]  J. Balligand,et al.  Erythropoietin preserves the endothelial differentiation capacity of cardiac progenitor cells and reduces heart failure during anticancer therapies. , 2011, Cell stem cell.

[6]  Andreas Bracher,et al.  Molecular chaperones in protein folding and proteostasis , 2011, Nature.

[7]  D. Cox,et al.  Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure , 2011, Science.

[8]  D. Pearce,et al.  Interactions of the proteins of neuronal ceroid lipofuscinosis: clues to function , 2011, Cellular and Molecular Life Sciences.

[9]  Bernd Bukau,et al.  Cellular strategies for controlling protein aggregation , 2010, Nature Reviews Molecular Cell Biology.

[10]  Dieter Braun,et al.  Protein-binding assays in biological liquids using microscale thermophoresis. , 2010, Nature communications.

[11]  H. Drexler,et al.  Continuous Glycoprotein-130-Mediated Signal Transducer and Activator of Transcription-3 Activation Promotes Inflammation, Left Ventricular Rupture, and Adverse Outcome in Subacute Myocardial Infarction , 2010, Circulation.

[12]  Jeffrey R. Moore,et al.  The molecular basis of frictional loads in the in vitro motility assay with applications to the study of the loaded mechanochemistry of molecular motors , 2010, Cytoskeleton.

[13]  B. Brenner,et al.  Targeted optimization of a protein nanomachine for operation in biohybrid devices. , 2010, Angewandte Chemie.

[14]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[15]  S. Loughna,et al.  Cardiomyopathy: A Systematic Review of Disease-Causing Mutations in Myosin Heavy Chain 7 and Their Phenotypic Manifestations , 2009, Cardiology.

[16]  D. Szczesna‐Cordary,et al.  Removal of the cardiac myosin regulatory light chain increases isometric force production , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  Sheena E Radford,et al.  An expanding arsenal of experimental methods yields an explosion of insights into protein folding mechanisms , 2009, Nature Structural &Molecular Biology.

[18]  D. Manstein,et al.  Dictyostelium Myosin-5b Is a Conditional Processive Motor* , 2008, Journal of Biological Chemistry.

[19]  H. Watkins,et al.  The molecular phenotype of human cardiac myosin associated with hypertrophic obstructive cardiomyopathy , 2008, Cardiovascular research.

[20]  A. Oldfors Hereditary myosin myopathies , 2007, Neuromuscular Disorders.

[21]  Dieter Braun,et al.  Why molecules move along a temperature gradient , 2006, Proceedings of the National Academy of Sciences.

[22]  Masoud Vedadi,et al.  Screening for Ligands Using a Generic and High-Throughput Light-Scattering-Based Assay , 2006, Journal of biomolecular screening.

[23]  C. Trautwein,et al.  JunD attenuates phenylephrine-mediated cardiomyocyte hypertrophy by negatively regulating AP-1 transcriptional activity. , 2006, Cardiovascular research.

[24]  J. Wade Harper,et al.  Drug discovery in the ubiquitin–proteasome system , 2006, Nature Reviews Drug Discovery.

[25]  D. Manstein,et al.  Changes in Mg2+ Ion Concentration and Heavy Chain Phosphorylation Regulate the Motor Activity of a Class I Myosin* , 2005, Journal of Biological Chemistry.

[26]  Michael D. Schneider,et al.  Signal Transducer and Activator of Transcription 3 Is Required for Myocardial Capillary Growth, Control of Interstitial Matrix Deposition, and Heart Protection From Ischemic Injury , 2004, Circulation research.

[27]  D. Manstein,et al.  Mutations in the relay loop region result in dominant‐negative inhibition of myosin II function in Dictyostelium , 2002, EMBO reports.

[28]  A. Lazou,et al.  α1- and β-adrenoceptor stimulation differentially activate p38-MAPK and atrial natriuretic peptide production in the perfused amphibian heart , 2002 .

[29]  G. Margaritondo,et al.  Reactivity of Au with ultrathin Si layers: A photoemission study , 2001 .

[30]  B. Harrison,et al.  Cardiac and skeletal muscle adaptations to voluntary wheel running in the mouse. , 2001, Journal of applied physiology.

[31]  D. Manstein,et al.  Charge changes in loop 2 affect the thermal unfolding of the myosin motor domain bound to F-actin. , 2000, Biochemistry.

[32]  D. Kass,et al.  Improved mechanoenergetics and cardiac rest and reserve function of in vivo failing heart by calcium sensitizer EMD-57033. , 2000, Circulation.

[33]  D. Manstein,et al.  Functional Characterisation of Dictyostelium Myosin II with Conserved Tryptophanyl Residue 501 Mutated to Tyrosine , 1999, Biological chemistry.

[34]  M F Sanner,et al.  Python: a programming language for software integration and development. , 1999, Journal of molecular graphics & modelling.

[35]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[36]  D. Manstein,et al.  Modulation of actin affinity and actomyosin adenosine triphosphatase by charge changes in the myosin motor domain. , 1998, Biochemistry.

[37]  M Anson,et al.  Myosin motors with artificial lever arms. , 1996, The EMBO journal.

[38]  D. Manstein,et al.  Overexpression of myosin motor domains in Dictyostelium: screening of transformants and purification of the affinity tagged protein , 1995, Journal of Muscle Research and Cell Motility.

[39]  K. Nakao,et al.  MOLECULAR BIOLOGY AND BIOCHEMISTRY OF NATRIURETIC PEPTIDE FAMILY , 1995, Clinical and experimental pharmacology & physiology.

[40]  J. Corrie,et al.  Direct, real-time measurement of rapid inorganic phosphate release using a novel fluorescent probe and its application to actomyosin subfragment 1 ATPase. , 1994, Biochemistry.

[41]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[42]  E. Lakatta,et al.  Stereoselective actions of thiadiazinones on canine cardiac myocytes and myofilaments. , 1993, Circulation research.

[43]  E. Lakatta,et al.  Enantiomeric dissection of the effects of the inotropic agent, EMD 53998, in single cardiac myocytes. , 1993, The American journal of physiology.

[44]  N. Beier,et al.  The Novel Cardiotonic Agent EMD 53 998 is a Potent “Calcium Sensitizer” , 1991, Journal of cardiovascular pharmacology.

[45]  E. Lakatta,et al.  A novel positive inotropic substance enhances contractility without increasing the Ca2+ transient in rat myocardium. , 1991, Journal of molecular and cellular cardiology.

[46]  S. Schiaffino,et al.  Myosin Isoenzymes in Normal and Hypertrophied Human Ventricular Myocardium , 1983, Circulation research.

[47]  S. Lehrer,et al.  Intrinsic fluorescence of actin. , 1972, Biochemistry.

[48]  Hamid Ghanbari,et al.  Rheumatic heart disease , 1936 .

[49]  D. Pearce,et al.  A novel interaction of CLN3 with nonmuscle myosin-IIB and defects in cell motility of Cln3(-/-) cells. , 2011, Experimental cell research.

[50]  K. Sutoh,et al.  Functional Characterization of the Amino-Terminal Region of Myosin-2 , 2006 .

[51]  A. Lazou,et al.  Alpha(1)- and beta-adrenoceptor stimulation differentially activate p38-MAPK and atrial natriuretic peptide production in the perfused amphibian heart. , 2002, The Journal of experimental biology.

[52]  F. Haddad,et al.  highlighted topics Plasticity in Skeletal, Cardiac, and Smooth Muscle Invited Review: Effects of different activity and inactivity paradigms on myosin heavy chain gene expression in striated muscle , 2000 .

[53]  B. Brenner,et al.  Force enhancement without changes in cross-bridge turnover kinetics: the effect of EMD 57033. , 1997, Biophysical journal.

[54]  S. Lowey,et al.  Preparation of myosin and its subfragments from rabbit skeletal muscle. , 1982, Methods in enzymology.

[55]  H. Scheraga,et al.  Experimental and theoretical aspects of protein folding. , 1975, Advances in protein chemistry.

[56]  L. Leinwand,et al.  Kent Academic Repository Versions of Research Enquiries Citation for Published Version Link to Record in Kar Identification of Functional Differences between Recombinant Human a and B Cardiac Myosin Motors , 2022 .